Summary The role of post-operative radiotherapy for patients with non-small-cell lung cancer (NSCLC) is unclear despite five previous randomised trials. One deficiency with these trials was that they did not include adequate TNM staging, and so the present randomised trial was designed to compare surgery alone (S) with surgery plus post-operative radiotherapy (SR) in patients with pathologically staged TI-2, NI-2, MO NSCLC. Between July 1986 and October 1993, 308 patients (154 S, 154 SR) were entered from 16 centres in the UK. The median age of the patients was 62 years, 74% were male, >85% had normal or near normal levels of general condition, activity and breathlessness, 68% had squamous carcinoma, 52% had had a pneumonectomy, 63% had NI disease and 37% N2 disease. SR patients received 40 Gy in 15 fractions starting 4-6 weeks post-operatively. Overall there was no advantage to either group in terms of survival, although definite local recurrence and bony metastases appeared less frequently and later in the SR group. In a subgroup analysis, in the NI group no differences between the treatment groups were seen, but in the N2 group SR patients appeared to gain a one month survival advantage, delayed time to local recurrence and time to appearance of the bone metastases. There is, therefore, no clear indication for post-operative radiotherapy in Nl disease, but the question remains unresolved in N2 disease.
For patients with potentially resectable, non-small-cell lung cancer (NSCLC) without distant metastases, the standard treatment is an intended curative resection. In 1986, at the time this trial was planned and activated, a number of studies had already clarified some of the factors affecting resectability and subsequent prognosis.
Firstly, it was already clear that the duration of subsequent survival was greatly reduced if the mediastinal nodes were found to be involved. For example, in a consecutive series of 245 patients undergoing curative resection, Wilkins et al. (1978) reported 5-year survival rates of 42% in patients without mediastinal node involvement compared with only 16% with such involvement. Greschuchna and Maassen (1980) reported corresponding rates of 37% and 11%, and broadly similar results were reported by others (Edwards, 1979; Mountain, 1986) .
Secondly, the importance of careful preoperative staging in the selection of patients suitable for intended resection was appreciated, particularly the need to avoid inappropriate thoracotomy in patients with T3 tumours, gross mediastinal node involvement or metastatic disease (Pearson, 1980; Spiro and Goldstraw, 1984) . This need can only be met if, in reported separately.
In the light of the above observations, the question arises whether, among patients adequately assessed for resection, post-operative radiotherapy prolongs survival in those with, and in those without, mediastinal node involvement (Perez, 1982) . A number of retrospective surveys claimed to show that it was of benefit to patients with mediastinal node metastases (Green et al., 1975; Kirsh et al., 1976; Choi et al., 1980; Chung et al., 1982; Newman et al., 1983) ; but these surveys were in general small and involved unreliable comparsions against either historical controls or other series from different centres.
Results from five randomised trials, however, were inconclusive and inconsistent. Paterson and Russell (1962) , in a trial of 202 patients randomised to pneumonectomy with or without post-operative mediastinal orthovoltage radiotherapy, showed no difference in survival, the 3-year survival rates being 36% in the no radiotherapy group and 33% in the radiotherapy group. However, the trial included 43 patients with poorly differentiated anaplastic or oat cell carcinoma, no TNM staging was done either before or during surgery, and the intake was stratified only by operating surgeon and patient's age; the influence on the result of histology, mediastinal node involvement and other variables of possible prognostic importance is uncertain. A study by Bangma (1971) is often mentioned in this context, but it was not a randomised trial; the patients were assigned alternatively to the two treatment groups. Even so, in this small study (73 patients) also, no benefit was shown for postoperative radiotherapy.
In an analysis involving 175 of 224 randomised patients with tumour confined to the lung, that is, with no intraoperative evidence of lymph node metastases (Van Houtte et al., 1980) , survival was better in the non-irradiated group, the 5-year survival rate being 43% in this group compared with 24% in the irradiated group. Although the survival difference was not statistically significant, the size of the effect observed raised the question whether post-operative mediastinal radiotherapy might be harmful in patients with NO or NI disease.
In a trial by the Lung Cancer Study Group (1986) (Naruke et al., 1978) were to be sampled, including at least two mediastinal stations, the main subcarinal nodes and (except for lower lobe tumours) the high paratracheal nodes. For lower lobe tumours, the paraoesophageal or pulmonary ligament nodes were to be sampled. The pathological N staging was made by the local histopathologist.
Treatment allocation Once the trial had been approved by the local ethics committee and individual patient consent was obtained, clinicians telephoned the MRC Cancer Trials Office between 2 and 4 weeks post-operatively to obtain a treatment allocation to either radiotherapy or no radiotherapy. Patients were allocated to one of the two regimens using a minimisation procedure stratifying for surgeon, TNM stage (TlNlMO, T2NlMO, TlN2MO, T2N2MO or unknown at time of randomisation) and histology (squamous, adenocarcinoma, large cell, other or unknown at time of randomisation).
Surgery with no post-operative radiotherapy (S) Patients in this group received no further specific anti-cancer treatment unless their disease recurred. Any subsequent treatment was given at the discretion of the individual clinician.
Surgery with post-operative radiotherapy (SR) Patients allocated to immediate post-operative radiotherapy received a course of radiotherapy to include the bronchial stump, mediastinal nodes and both lung hila, given in accordance with local practice, starting 4 to 6 weeks after the date of operation. If the tumour was in an upper lobe or if high mediastinal nodes were involved, the field included both supraclavicular fossae. The upper border of the field was never lower than the supraclavicular notch and the lower border extended at least 3 cm below the carina. The central midline dose was 40 Gy given in daily fractions (f) 5 days a week over 3 weeks using megavoltage x-ray therapy or 'Co gamma-ray teletherapy. Parallel opposed fields were to be $0 Patients in the S group were seen and assessed at 6 and 9 weeks from operation, and those in the SR group at the start and end of radiotherapy. Both groups were then seen at 4, 6, 9, 12, 18 and 24 months from operation, and annually thereafter. The follow-up reports included details of the patient's blood counts, any evidence of recurrence of the primary cancer, metastases and any anti-cancer treatment. Clinicians reported the presence of recurrence and metastases as 'definite' or 'suspected' according to whatever evidence was available to them. They also reported the patients' general condition, WHO performance status and degree of breathlessness.
All patients were followed to death, even if they were subsequently found not to have satisfied the eligibility criteria for the trial, or if they did not for any reason receive the allocated treatment.
Statistical methods
All analyses are based on the intention to treat principle (Lewis and Machin, 1993 The trial data were managed using the COMPACT program (COMPACT Steering Committee, 1991) .
The proposed intake of 300 patients was based on the calculation that 5-year survival rates of 20% (S group) and 36% (SR group) would provide a 90% chance of obtaining a significant result at the 5% level. It was recognised that these figures were approximate because of the unpredictable mix of patients with NI and N2 disease. It was hoped that this intake would be accrued within 3 years.
Results
Patients in the trial Between July 1986 and October 1993 308 patients were admitted from 16 centres in the UK. Exactly half (154) were allocated to each treatment. Table I shows the staging procedures used and the numbers considered abnormal, suspicious and normal. The majority of patients had chest radiography (97%) and a bronchoscopy (95%) and of these 94% and 72%, respectively, were abnormal. A total of 73% of the patients had a CT chest scan and 95% of these were considered abnormal. Only a small proportion of patients had cervical mediastinoscopy (8%), anterior mediastinoscopy (3%) and mediastinotomy (2%).
Preoperative characteristics
Most patients (229, 74%) also had additional staging procedures to exlcude the presence of metastases. Table I shows that 38% of patients had a CT of the upper abdomen and 39% an abdominal ultrasound (five patients having both). The other investigations suggested in the protocol were very rarely used. Using these additional staging procedures, abnormalities were observed in five patients (3S, 2SR), but none of these were considered to be caused by metastases.
Nearly all the patients (Table II) had normal or near normal categories (grades 0 or 1) of general condition (90%), performance status (97%) and breathlessness (85%). The majority were male (74%), and at operation the median age was 62 years (range 37-77 years). No patients had an abnormally low (<3000 mm-3) white blood cell count or low platelet count (< 100000 mm-3), but six patients (2S, 4SR) had a haemoglobin of < 10.0 g dl-1 and three (2S, 1SR) a high white cell count of >20000 mm Operative and post-operative characteristics Fifty-two per cent of the patients (Table III) had had a pneumonectomy (48% of the patients with NI disease, 58% of those with N2) and 45% a lobectomy (48% of those with NI, 41% of those with N2). The majority had squamous carcinoma (68%) and the site of disease was left upper lobe in 36%, right upper lobe in 22%, left lower lobe in 15% and right lower lobe in 13%.
The median number of node groups sampled was three (range 0-9), and of these a median of one was found to be involved. The majority (85%) of patients in whom the hilar nodes were the most central group involved were classified as having NI disease. As reported over the telephone at the time of randomisation, 47% of the patients had T2NlMO disease, 29% T2N2MO, 16% TINIMO and only 8% TIN2MO.
The median time from operation to randomisation was 15 days (range 3-167 days), 133 (43%) being earlier and 41 (13%) later than the protocol recommendation of 14-28 days.
The distributions of all the above characteristic between the two regimens were very similar.
Ineligible patients Seventeen patients (lOS, 7SR) did not fit the exact eligibility criteria as laid down in the protocol: two (both S) had no evidence of lymph node involvement, two (both SR) had bronchial margins involved, one (S) had lung metastases, one (SR) had had previous radiotherapy for breast cancer Of the 136 patients who did receive their allocated course of post-operative radiotherapy, 55 (36% of the 154 patients allocated) had radiotherapy given exactly as specified in the protocol, and 21 patients (14%) had minor deviations, Table IV shows the number of patients in whom distant metastases were suspected or confirmed. The patterns of failure were very similar for the two regimens. Overall, distant metastases developed in 67% of the S group compared with 51% of the SR group, and the major sites were bone and brain. The log-rank test was used to check if there were differences in the time to occurrence. The upper section of Figure 3 shows the KM plots for the appearance of any metastases. Although the curves diverge at approximately 1 year, there was no overall difference (HR 1.28, 95% CI 0.95-1.71, P=0.10). The only specific site in which a significant difference was observed was bone (lower section of Figure 3) , and in the S group bony metastases were more common and developed earlier (HR 2.09, 95% CI 1.35-3.22, P=0.001). Analyses using only confirmed metastases gave very similar results.
Changes in general condition, performance status and breathlessness Comparing the percentages of patients with impaired (grade 2, 3 or 4) general condition, performance status and breathlessness at each of the nine assessments up to 2 years showed, for all three variables, that patients allocated to SR had a period of worse condition during and just after their radiotherapy (month 1), but thereafter no differences between the two regimens were observed (data not shown). (Holmes, 1994; Ginsberg, 1994a, b; Rosell et al., 1994a; Non-small Cell Lung Cancer Collaborative Group, 1995) . The definitive results of three more recent randomised trials in patients with N, 2 disease (Ricci et al., 1991; Mei et al., 1994; Debevec et al., 1995) are awaited.
The overall results of the present trial confirm previous studies in that there was no advantage to survival in the SR group over that of surgery alone. The non-significant trend towards improved survival in the N2 group is matched by a similar trend of reduced local recurrence in this subgroup. However, a total of only 106 N2 cases makes such subgroup analysis unlikely to demonstrate modest but clinically important differences. A meta-analysis to include this present trial with other published and unpublished randomised trials is in progress and particular attention will be paid to the nodal status of patients.
The most striking difference between the two treatment policies was in the incidence of distant metastases. While the results for the NI group were generally similar, the incidence of bone metastases was higher in the S group. In the N2 patients there was a highly significant excess of bone metastases in the S group. The appearance of bone metastases occurred steadily over the 3-4 years following treatment. Moreover, this large excess of bony mestatases was not simply the result of a relative failure to control local disease in the S group; there was, in fact, no evidence of an association between local recurrence and bony metatases.
There was a modest increase in side-effects following the post-operative radiotherapy over those recorded for the S group. However, these were not of sufficient magnitude to be regarded as a contraindication to the treatment.
In conclusion, this trial has provided no convincing evidence that post-operative radiotherapy affects survival, local recurrence or the development of metastases in patients with pathologically staged NI disease. In patients with N2 disease, it substantially reduced metastases and probably local recurrence. It will be important to determine in longer term follow-up whether this latter finding is confirmed and whether radiotherapy also led to a small improvement in survival. The radiotherapy dose and techniques, although standard at the time the trial was opened, would not now be regarded as ideal, because some midline mediastinal nodes would receive a lower dose as a result of the posterior spinal cord shielding; the dose to a 1-2 cm midline strip would be reduced to about 38-39 Gy at the midplane, where most of the mediastinal nodes lie. However, following surgery there is usually a shift of the mediastinum towards the treated side and so the effect of a midline shield may be of little importance. It is arguable that larger doses given by modern techniques could have had greater effect. It is important that in future the role of radiotherapy in preoperative schedules involving chemotherapy be determined (Holmes and Ruckdeschel, 1993; Rosell et al., 1994b) .
